NASDAQ:CLSN - Celsion Stock Price, Forecast & News

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Celsion shares reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings data on Friday, November, 15th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.05. The biotechnology company earned $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. View Celsion's Earnings History.

Celsion is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Celsion.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion.

Media coverage about CLSN stock has trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Celsion earned a news impact score of 2.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Celsion.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Rexahn Pharmaceuticals (REXN), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), NovaBay Pharmaceuticals (NBY), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Novavax (NVAX) and Tesla (TSLA).

Celsion's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.35%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View Institutional Ownership Trends for Celsion.

CLSN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View Insider Buying and Selling for Celsion.

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLSN stock can currently be purchased for approximately $1.35.